GlassScriptPhysician profile
Tuyet Nguyen
NPI 1396974671
$8,482.08
in general payments reported to CMS, 2019-2025
34 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,728 · 2022: $1,516 · 2023: $1,619 · 2024: $1,738 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,237.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,389.45 | 2021-2025 | Freestyle Libre 2, Proclaim, Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $800.00 | 2021 | |
| Amgen INC. | $782.71 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $583.51 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $566.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $423.16 | 2021-2024 | Coveredge 32 |
| Intra-Sana Laboratories | $349.81 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Lucid Diagnostics INC. | $279.74 | 2022-2024 | |
| W. L. Gore & Associates, INC. | $243.13 | 2023 | Gore Cardioform Septal Occluder |
| Phathom Pharmaceuticals, INC. | $240.80 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $232.68 | 2022 | |
| Dexcom, INC. | $229.62 | 2021-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.32 | 2021-2025 | Jardiance |
| Pfizer INC. | $214.59 | 2023-2025 | |
| Lilly USA, LLC | $213.66 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.80 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.48 | 2022-2025 | |
| Exact Sciences Corporation | $157.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Asahi Intecc USA, INC. | $154.92 | 2024 | Peripheral Vascular |
| Astellas Pharma US INC | $151.56 | 2025 | Veozah |
| Nevro Corp. | $149.79 | 2023 | Senza |
| Janssen Pharmaceuticals, INC | $122.53 | 2022 | |
| Abbvie INC. | $102.29 | 2023 | |
| Daiichi Sankyo INC. | $98.44 | 2024-2025 | Injectafer |
| Horizon Therapeutics Plc | $93.71 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $53.04 | 2022-2024 | Quviviq |
| Genentech USA, INC. | $46.54 | 2021-2022 | |
| Glaxosmithkline, LLC. | $43.19 | 2023-2024 | Arexvy, Shingrix |
| Medline Industries LP | $42.69 | 2021 | |
| Tactile Systems Technology INC | $32.25 | 2023-2024 | Flexitouch Plus, Entre Plus |
| Merck Sharp & Dohme LLC | $31.32 | 2021 | |
| Inogen, INC. | $21.00 | 2025 | |
| Amarin Pharma, INC. | $19.57 | 2021 | |
| Phadia US INC. | $13.92 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuyet Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.